Occurrence of pituitary hormone deficits in relation to both pituitary and hypothalamic doses after radiotherapy for skull base meningioma.
brain tumour
endocrine deficit
hypopituitarism
hypothalamus
pituitary
radiotherapy
skull base meningioma
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
28
04
2021
received:
01
02
2021
accepted:
10
05
2021
pubmed:
25
5
2021
medline:
28
10
2021
entrez:
24
5
2021
Statut:
ppublish
Résumé
Little accurate information is available regarding the risk of hypopituitarism after irradiation of skull base meningiomas. Retrospective study in a single centre. 48 patients with a skull base meningioma and normal pituitary function at diagnosis, treated with radiotherapy (RXT) between 1998 and 2017 (median follow-up of 90 months). The GH, TSH, LH/FSH and ACTH hormonal axes were evaluated yearly for the entire follow-up period. Mean doses delivered to the pituitary gland (PitD) and the hypothalamus (HypoD) were calculated, as well as the doses responsible for the development of deficits in 50% of patients after 5 years (TD50). At least one hormone deficit was observed in 38% of irradiated patients and complete hypopituitarism in 13%. The GH (35%), TSH (32%) and LH/FSH axes (28%) were the most frequently affected, while ACTH secretion axis was less altered (13%). The risk of hypopituitarism was independently related to planning target volume (PTV) and to the PitD (threshold dose 45 Gy; TD50 between 50 and 54 Gy). In this series, the risk was less influenced by the HypoD, increasing steadily between doses of 15 and 70 Gy with no clear-cut dose threshold. Over a median follow-up period of 7.5 years, hypopituitarism occurred in more than one third of patients irradiated for a skull base meningioma, and this prevalence was time- and dose-dependent. In this setting, the risk of developing hypopituitarism was mainly determined by the irradiated target volume and by the dose delivered to the pituitary gland.
Substances chimiques
Pituitary Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
460-468Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Merchant TE, Goloubeva O, Pritchard DL, et al. Radiation dose-volume effects on growth hormone secretion. Int J Radiat Oncol Biol Phys. 2002;52(5):1264-1270.
Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011;29(36):4776-4780.
Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumours and radiotherapy. Pituitary. 2005;8(3-4):203-211.
Bhandare N, Kennedy L, Malyapa RS, Morris CG, Mendenhall WM. Hypopituitarism after radiotherapy for extracranial head and neck cancers. Head Neck. 2008;30(9):1182-1192.
Kyriakakis N, Lynch J, Orme SM, et al. Hypothalamic-pituitary axis irradiation dose thresholds for the development of hypopituitarism in adult-onset gliomas. Clin Endocrinol. 2019;91(1):131-140.
Madaschi S, Fiorino C, Losa M, et al. Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors. Radiother Oncol. 2011;99(1):23-28.
Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab. 2005;90(12):6355-6360.
Pai HH, Thornton A, Katznelson L, et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;49(4):1079-1092.
Vatner RE, Niemierko A, Misra M, et al. Endocrine deficiency as a function of radiation dose to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. J Clin Oncol. 2018;36(28):2854-2862.
Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245-4253.
Lambrecht M, Eekers DBP, Alapetite C, et al. Radiation dose constraints for organs at risk in neuro-oncology; the European particle therapy network consensus. Radiother Oncol. 2018;128(1):26-36.
Heinze G, Wallisch C, Dunkler D. Variable selection-A review and recommendations for the practicing statistician. Biometrical journal Biometrische Zeitschrift. 2018;60(3):431-449.
Kyriakakis N, Lynch J, Orme SM, et al. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. Clin Endocrinol. 2016;84(3):372-379.
Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary. 2009;12(1):40-50.
Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med. 1989;70(262):145-160.
Persani L, Brabant G, Dattani M, et al. 2018 European thyroid association (ETA) guidelines on the diagnosis and management of central hypothyroidism. Eur Thyroid J. 2018;7(5):225-237.
Beck-Peccoz P, Rodari G, Giavoli C, Lania A. Central hypothyroidism-a neglected thyroid disorder. Nat Rev Endocrinol. 2017;13(10):588-598.
Follin C, Erfurth EM. Long-term effect of cranial radiotherapy on pituitary-hypothalamus area in childhood acute lymphoblastic leukemia survivors. Curr Treat Options Oncol. 2016;17(9):50.
De Marzi L, Feuvret L, Boule T, et al. Use of gEUD for predicting ear and pituitary gland damage following proton and photon radiation therapy. Br J Radiol. 2015;88(1048):20140413.
Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours. Endocr Relat Cancer. 2004;11(4):589-602.
Ragel BT, Jensen RL. Molecular genetics of meningiomas. Neurosurg Focus. 2005;19(5):1-8.